Prognosis and Prognostic Index



Through clinical trials of intensive chemotherapy for patients with aggressive adult T-cell leukemia-lymphoma (ATL) (i.e., acute, lymphoma, or unfavorable chronic type), 5-year overall survival has improved from 5% in the 1980s to 15% in the 1990s. Comparatively, the median survival time (MST) of patients with indolent ATL (i.e., favorable chronic or smoldering) was 3–7 years with watchful waiting as the standard treatment. Recently, two types of prognostic indices (PIs) for aggressive ATL were published. A prognostic index for acute- and lymphoma-type ATL (ATL-PI) was reported in a retrospective analysis using the medical records of 807 patients in Japan. ATL-PI based on the Ann Arbor stage, Eastern Cooperative Oncology Group performance status, age, serum albumin, and soluble interleukin-2 receptor identified low-, intermediate-, and high-risk groups with MST of 16, 7, and 5 months, respectively. The Japan Clinical Oncology Group (JCOG)-PI was established by evaluating the clinical features of 276 patients with aggressive ATL in three consecutive JCOG trials. In multivariate analysis of 193 patients, the JCOG-PI based on corrected calcium levels and PS identified moderate- and high-risk groups with MST of 14 and 8 months, respectively. Both PIs are valuable for identifying patients with an extremely poor prognosis.


Aggressive ATL Indolent ATL Prognostic index ATL-PI JCOG-PI 


  1. 1.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–1987). Br J Haematol. 1991;79:428–37.CrossRefPubMedGoogle Scholar
  2. 2.
    Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-cell leukemia. Oxford: Oxford University Press; 1994. p. 221–37.Google Scholar
  3. 3.
    Lymphoma Study Group. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study-Lymphoma Study Group (1984–1987). Leuk Res. 1991;15:81–90.CrossRefGoogle Scholar
  4. 4.
    Tobinai K, Watanabe T. Adult T-cell leukemia-lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MCB, editors. Clinical oncology. 3rd ed. Philadelphia: Elsevier Churchill Livingstone. p. 3109–30.Google Scholar
  5. 5.
    Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, Ichimaru M, Ogawa M, Kimura I, Tominaga S. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988;6:128–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Tobibai K, Shimoyama M, Minato K, Shirakawa S, Kobayashi T, Hotta T. Japan Clinical Oncology Group phase II trial of second-generation “LSG4 protocol” in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma. Proc Am Soc Clin Oncol. 1994;13:378.Google Scholar
  7. 7.
    Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, Tomonaga M, Araki K, Kasai M, Takatsuki K, Tara M, Mikuni C, Hotta T, Lymphoma Study Group of the Japan Clinical Oncology Group. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77:164–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M, Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Ishitsuka K, Ikeda S, Utsunomiya A, Saburi Y, Uozumi K, Tsukasaki K, Etou K, Muta K, Kinosita K, Tamura K. Smouldering adult T-cell leukaemia/lymphoma: a follow-up study in Kyushu. Br J Haematol. 2008;143:442–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, Maeda T, Hirakata Y, Kamihira S, Tsukasaki K, Ogawa S, Hirai H, Koeffler HP, Tomonaga M. Deletion of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Utsunomiya A, Ishida T, Inagaki A, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y, Ueda R. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res. 2007;31:915–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M. Impact of visceral involvement and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res. 2007;31:751–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer. 2006;118:3054–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushita K, Ueda R. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625–34.PubMedGoogle Scholar
  17. 17.
    Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood. 2001;98:1160–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Tawara M, Hogerzeil SJ, Yamada Y, Yakasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S. Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma. Cancer Lett. 2006;234:249–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Suzumiya J, Tamura K. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, Tomoyose T, Uozumi K, Kobayashi Y, Fukushima N, Utsunomiya A, Tara M, Nosaka K, Hidaka M, Uike N, Yoshida S, Tamura K, Ishitsuka K, Kurosawa M, Nakata M, Fukuda H, Hotta T, Tobinai K, Tsukasaki K. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739–48.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  1. 1.Department of Clinical Laboratory Sciences, School of Health SciencesUniversity of the RyukyusOkinawaJapan

Personalised recommendations